Comparison studies of ultrasound-guided botulinum toxin injection and balloon catheter dilatation in the treatment of neurogenic cricopharyngeal muscle dysfunction

Article type: Research Article

Authors: Luan, Shuo^{a; 1} | Wu, Shao-Ling^{a; 1} | Xiao, Ling-Jun^a | Yang, Hai-Yun^b | Liao, Mei-Xin^a | Wang, Shao-Ling^a | Fan, Sheng-Nuo^a | Ma, Chao^{a; *}

Affiliations: [a] Department of Rehabilitation, Sun Yat-sen Memorial Hospital, Guangzhou, People’s Republic of China | [b] Department of Ultrasonic, Sun Yat-sen Memorial Hospital, Guangzhou, People’s Republic of China

Correspondence: [*] Address for correspondence: Chao Ma, Department of Rehabilitation Medicine, Sun Yat-sen Memorial Hospital, No. 107 Yanjiang West Road, Guangzhou, China. Tel.: +02081332513; E-mail: [email protected].

Note: [1] Shuo Luan and Shao-ling Wu contributed equally to this work.

Abstract: BACKGROUND:Cricopharyngeal muscle dysfunction (CPD) management has been challenging in clinical practice. OBJECTIVE:To compare the efficacy and safety of ultrasound-guided botulinum toxin injection and balloon catheter dilatation in treating CPD. METHODS:Forty patients with CPD were randomly divided into two groups, namely the botulinum toxin injection group (BTX group) and balloon dilatation group (BD group). Patients in the BTX group received a single ultrasound-guided injection of 50 units of botulinum toxin type A, while the BD group received dilatation therapy five times per week, consecutively for two weeks. Relative opening percentage of the upper esophageal sphincter (UES), the penetration-aspiration scale (PAS), and the Dysphagia Outcome Severity Scale (DOSS) were evaluated by a videofluoroscopic swallowing study (VFSS) at baseline, 1-month, and 3-months posttreatment. The Functional Oral Intake Scale (FOIS) and Standardized Swallowing Assessment (SSA) were also used to evaluate participants’ swallowing function at baseline and the 1-week, 2-week, 1-month, and 3-month follow-ups. RESULTS:A generalized estimating equation (GEE) model revealed the significant main effect for time in UES, PAS, DOSS, FOIS, and SSA compared to baseline (P <0.05), while no group-by-time interactions (except for the PAS assessment) or main effect for treatment was detected among the above multiple variances. No systematic complications or severe adverse effects were noted. CONCLUSION:Both ultrasound-guided botulinum toxin type A injections and balloon dilatation therapy have been proven as safe and effective treatments for CPD patients. Future clinical trials with longer follow-up periods and more participants are warranted.

Keywords: Neurogenic cricopharyngeal muscle dysfunction, ultrasound-guided botulinum toxin injection, balloon catheter dilatation therapy, dysphagia

DOI: 10.3233/NRE-210113

Journal: NeuroRehabilitation, vol. 49, no. 4, pp. 629-639, 2021